8.13 (-%)
As of Nov 21, 2024
Source:
We are a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for people living with cancer. We leverage our deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the aim of restoring the immune response against cancer. Our innovative pipeline includes two clinical-stage programs targeting novel, de-risked immuno-oncology pathways. Each of our therapies in development has optimized pharmacologic properties designed to improve clinical outcomes.
Country | United States |
Headquarters | watertown, massachusetts |
Phone Number | 857-204-4583 |
Industry | manufacturing |
CEO | Michel Detheux |
Website | www.clinicaltrials.gov |